S

Sanofi

Global pharma company; vaccines and R&D

Global Head Regulatory Science - Multiple Teams

Full-TimeDeadline 10/2/26
$266.3k - $384.6k/yr
Expert
Bachelor's, Master's, PharmD, PhD
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
In PersonApproximately 10% domestic and international travel is expected.

About the job

Requirements
  • A minimum of 10–15 years of regulatory affairs experience with demonstrated progression in regulatory roles and successful regulatory authority interactions.
  • Direct experience with Model-Informed Drug Development, pharmacometrics, modeling and simulation, and/or novel endpoint development is highly desirable.
  • A proven track record of successful regulatory submissions involving advanced modeling approaches or innovative endpoints.
  • Leadership experience building and developing specialized teams, including organizational design, people leadership and development, supervision, coaching, mentoring, recruitment, retention, talent management, and succession planning.
  • Ability to lead through influence in a matrix organization and drive cross-functional collaboration.
  • Strong knowledge of model-enabled frameworks, including the FDA Model-Informed Drug Development Pilot Program, regulatory pathways for novel endpoint validation, and key agency thinking and trends in regulatory science innovation.
  • Ability to resolve complex strategic technical and regulatory issues related to modeling, simulation, and endpoint development.
  • A Bachelor's degree is required.
  • Excellent communication and influencing skills, including the ability to translate complex technical concepts for diverse audiences.
  • Ability to build and maintain effective partnerships with health authorities, research and development functions, and external stakeholders including industry consortia.
  • Ability to assess regulatory risks and opportunities in emerging areas, develop pragmatic and innovative solutions aligned with business objectives, and anticipate future regulatory trends.
  • Experience building and maintaining effective partnerships across functions, particularly with Translational Medicine, Clinical Development, Biostatistics, and Medical Affairs, and with external stakeholders.
  • Ability to drive knowledge sharing and capability building across organizations.
Responsibilities
  • Provide leadership and strategic vision for the expert unit, including organizational design, people development, supervision, coaching, mentoring, resource allocation, recruitment, retention, talent development, succession planning, and performance metrics.
  • Resolve and advise on complex global organizational and regulatory or technical issues related to model-enabled development, regulatory real-world evidence, and novel endpoint strategies.
  • Establish the team as a center of excellence for model-enabled regulatory strategies and submissions.
  • Develop and implement comprehensive regulatory strategy frameworks for Model-Enabled Drug Development across all development phases.
  • Lead regulatory validation projects, such as C-Peptide endpoint validation and iBox, from concept through approval while aligning with research and development product timelines.
  • Partner with Translational Medicine, Clinical Development, Biostatistics, and other research and development functions to implement appropriate model-enabled and real-world evidence regulatory strategies.
  • Integrate regulatory considerations early in development projects and identify, communicate, and mitigate risks.
  • Oversee strategic negotiations and engagement with worldwide regulatory agencies, including the FDA and EMA, on model development topics, Model-Informed Drug Development approaches, real-world evidence, and novel endpoints.
  • Develop and implement health authority engagement plans to advance acceptance of innovative regulatory strategies.
  • Represent Sanofi at agency meetings and scientific working groups and manage agency contacts effectively and promptly.
  • Provide vision and leadership for building specialized regulatory expertise in model-enabled development and real-world evidence approaches across the global GRA organization.
  • Oversee creation and dissemination of best practices, standard operating procedures, training materials, knowledge management platforms, and case studies.
  • Partner with the Regulatory Capability and Learning Solution Lead to develop and deliver training curricula and capability development programs.
  • Monitor and communicate current health authority thinking, regulatory trends, and paradigm shifts in model-enabled development, real-world evidence, and novel endpoints.
  • Lead external participation in industry consortia, working groups, and professional associations.
  • Oversee preparation, review, and approval of model-enabled regulatory submissions and real-world evidence and novel endpoint validation packages.
  • Drive cross-functional project delivery efficiency through matrix collaboration with research and development counterparts.
  • Resolve complex technical and regulatory issues related to modeling, simulation, and new endpoints with optimal solutions.
  • Establish governance and decision-making processes to enable efficient project execution and milestone achievement.
Desired Qualifications
  • Direct experience with Model-Informed Drug Development, pharmacometrics, modeling and simulation, and/or novel endpoint development.
  • Experience establishing centers of excellence or expert units.
  • Experience working with or for a regulatory health authority.
  • An advanced degree—Master's, PharmD, or PhD—in a quantitative science or health sciences field, such as Pharmacology, Clinical Pharmacology, Translational Medicine, Computational Biology, Pharmacometrics, or Biostatistics, or equivalent.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi completed Vicebio on December 4, 2025, adding RSV-HMPV vaccine technology.
  • Sanofi completed Dynavax on February 10, 2026, expanding hepatitis B and shingles assets.
  • FDA approved wearable Sarclisa on July 2026, improving multiple myeloma convenience.

What critics are saying

  • Dupixent loses patent exclusivity in 2031, exposing Sanofi’s cash engine.
  • EU regulators opened a June 26, 2026 antitrust probe over Efluelda marketing.
  • Sanofi sued Pfizer and Moderna on July 15, 2026 over COVID-shot patents.

What makes Sanofi unique

  • Dupixent and partner Regeneron still anchor Sanofi’s immunology franchise in 2026.
  • Vicebio’s Molecular Clamp and Dynavax deepen Sanofi’s respiratory and adult vaccine platform.
  • Frankfurt insulin manufacturing, backed by Germany’s 2026 subsidy, protects European supply security.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...